ArticleTherapeutic advances in musculoskeletal disease2025
Association between cumulative TNF inhibitor dose and spinal radiographic progression in radiographic axial spondyloarthritis in patients with modified stoke ankylosing spondylitis spinal score ⩽24.
Article in Therapeutic advances in musculoskeletal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research Advances on the Mechanism and Diagnosis of Bone Bridging in Ankylosing Spondylitis.Orthopedic research and reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor necrosis factor inhibitors (TNFi) effectively manage radiographic axial spondyloarthritis (SpA), and dose reduction is often used for stable patients. However, its long-term impact on radiographic progression remains unclear. Objective: To analyze the correlation between cumulative TNFi dose and radiographic progression in radiographic axial SpA. Design: Single-center retrospective chart review. Methods: Electronic medical records of patients with radiographic axial SpA from January 2001 to December 2018 were screened. The TNFi percentage dose was calculated as the total prescribed dose divided by the standard dose at 2-year intervals. The relationship between TNFi percentage dose and modified Stokes Ankylosing Spondylitis Spinal Score (mSASSS) changes was assessed using linear mixed models, separated into three baseline mSASSS groups: mSASSS ⩽24, mSASSS >24 to ⩽48, and mSASSS >48. Results: In the initial linear mixed model, radiographic progression, defined as the change in mSASSS over 2-year intervals, was examined in three baseline mSASSS groups. In the baseline mSASSS ⩽24 group, the cumulative TNFi dose showed a negative correlation with radiographic progression (β = -0.888, 95% confidence interval (CI): -1.793 to 0.017, Conclusion: In patients with radiographic axial SpA and baseline mSASSS ⩽24, the cumulative TNFi dose was negatively correlated with radiographic progression. Maintaining a standard TNFi dose may slow the progression of spinal structural changes in early stage SpA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.